Navigation Links
Helix BioPharma closes $16.9 million private placement of common shares
Date:12/19/2007

AURORA, ON, Dec. 19 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced the closing of its previously announced private placement, for gross proceeds of CDN$16,867,200.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains forward-looking statements regarding a proposed private placement and the Company's activities, which statements can be identified by the words "will", "anticipates", and "developing". Actual results or events could differ materially from these forward-looking statements due to numerous factors, including without limitation, the risk that the proposed placement may not close as anticipated or at all, research & development risks, Helix's need for additional future capital, the risk of unanticipated expenses, and possible changes in business strategy or plans. These and other risks and uncertainties are contained in Helix's latest Annual Information Form at http://www.sedar.com. Forward-looking statements and information are based on the assumptions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement or information should those assumptions or expectations, or other circumstances change.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
10. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
11. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... ... release, Clinical Studio Version 4.1, greatly improves performance of the platform. In particular, ... often generate tremendous volumes of data to be collected on a per patient ...
(Date:5/5/2016)... ON (PRWEB) , ... May 05, 2016 , ... ... following the previously announced identification of its first three targets, it has identified ... misfolded Amyloid beta (Aß), implicated in the development and progression of Alzheimer’s disease ...
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, 2016 , ... ... neurofibromatosis (NF), a genetic disorder that causes tumors to grow on nerves throughout the ... treatment or cure. , Through numerous community events held during the month of May, ...
(Date:5/3/2016)... San Francisco, CA (PRWEB) , ... May 03, ... ... Morf Playbook™ enterprise talent development, skill-building and compliance training platform on ... Direct training course: Overview of Regulatory Requirements for Medical Devices. The course ...
Breaking Biology Technology:
(Date:3/10/2016)... --> --> ... and Access Management Market by Component (Provisioning, Directory Services, ... Organization Size, by Deployment, by Vertical, and by Region ... market is estimated to grow from USD 7.20 Billion ... a Compound Annual Growth Rate (CAGR) of 12.2% during ...
(Date:3/9/2016)... 2016 Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> Nigeria ... more than 23,000 public service employees either did not ... their salary unlawfully.    --> DERMALOG, the ...
(Date:3/3/2016)... -- FlexTech, a SEMI Strategic Association Partner, awarded five FLEXI ... Leadership in Education, and, in a category new this ... year of the FLEXI Awards and the winners join ... past years . Judging was done on a set ... by a panel of non-affiliated, independent, industry experts. ...
Breaking Biology News(10 mins):